Plasma Adrenomedullin level in Egyptian children and Adolescents with type 1 diabetes mellitus: relationship to microvascular complications
© El-Habashy et al; licensee BioMed Central Ltd. 2010
Received: 21 November 2009
Accepted: 10 February 2010
Published: 10 February 2010
Adrenomedullin (AM) is known to be elevated in different clinical situations including diabetes mellitus (DM), but its potential role in the pathogenesis of vascular complications in diabetic children and adolescents is to be clarified. Hence, the study aimed at assessment of plasma adrenomedullin levels in children and adolescents with type 1 DM and correlation of these levels with metabolic control and diabetic microvascular complications (MVC).
The study was performed in the Diabetes Specialized Clinic, Children's Hospital of Ain Shams University in Cairo, Egypt. It included 55 diabetic children and adolescents (mean age 13.93 ± 3.15 years) who were subdivided into 40 with no MVC and 15 with MVC. Thirty healthy subjects, age-and sex- matched were included as control group (mean age 12.83 ± 2.82 years). Patients and controls were assessed for glycosylated hemoglobin (HbA1c) and plasma adrenomedullin assay using ELISA technique.
Mean plasma AM levels were significantly increased in patients with and without MVC compared to control group, (110.6 pg/mL, 60.25 pg/mL and 39.2 pg/mL respectively) (P < 0.01) with higher levels in those with MVC (P < 0.05). Plasma AM levels were positively correlated with both duration of diabetes (ρ = 0.703, P < 0.001) and glycemic control (HbA1c) (ρ = 0.453, P < 0.001).
Higher plasma AM levels in diabetics particularly in those with MVC & its correlation with diabetes duration and metabolic control may reflect the role of AM in diabetic vasculopathy in the pediatric age group.
Adrenomedullin (AM), a ubiquitous regulatory peptide with different actions, is expressed in many tissues throughout the body including the adrenal medulla, endothelial  and vascular smooth muscle cells , myocardium and central nervous system [3, 4]. Adrenomedullin (AM) is widely synthesized and secreted from most of the cells in the body . It controls proliferation, differentiation and migration of cells . Adrenomedullin (AM) is able to act as an autocrine, paracrine, or endocrine mediator in a number of biologically significant functions . It plays a critical role in several diseases such as cancer, diabetes, cardiovascular and renal disorders [8, 9]. It has vasodilator and blood pressure lowering properties and plays important role in maintaining electrolyte and fluid homeostasis . Endogenous AM may protect from organ damage by inhibiting oxidative stress production  and raised AM levels correlated with increased oxidative stress . Moreover, evidence that AM possesses a clear cut proangiogenic effect under both physiological and pathophysiological conditions has accumulated [13–15]. Adrenomedullin is involved in insulin regulatory system [16–18] and is elevated in plasma from patients with pancreatic dysfunctions such as type 1 or type 2 diabetes and insulinoma . Adrenomedullin might play a role in the pathogenesis of diabetic vasculopathy in type 1 and type 2 diabetes . However, to the best of our knowledge, there is no published data about AM level in type 1 diabetic children and adolescents. Hence, this study aimed at assessment of plasma adrenomedullin levels in type 1 diabetic children and adolescents and correlating levels with metabolic control and diabetic microangiopathy.
Materials and methods
This case control study included 55 consecutive type 1 diabetic children and adolescents recruited from Diabetology Clinic, Children's Hospital, Ain Shams University, Cairo, Egypt during the period from May 2004 to May 2006. Those with liver disease, renal failure or congestive heart failure were excluded . According to the presence or absence of MVC, patients were classified into: Group 1: 40 diabetic patients without MVC. Group 2 comprised 15 diabetic patients with MVC (retinopathy, neuropathy and/or nephropathy). Thirty apparently healthy age and sex matched children and adolescents were included as a control group. Informed consent was obtained from patients' parents or their legal guardians after study approval by the Local Ethical Committee, Ain Shams University (FWA00006444).
Patients were subjected to careful history taking laying stress on onset, duration, frequency of diabetic ketoacidosis (DKA) or hyperglycemic attacks, thorough clinical examination with special emphasis on signs of diabetic complications. Fundus examination was performed by an ophthalmologist after maximum papillary dilatation using indirect ophthalmoscope to identify diabetic retinopathic changes .
Assessment of glycemic control by calculating the mean glycosylated hemoglobin (HbA1c) over the last year was performed using high performance liquid chromatography (HPLC) technique . Patients were considered under optimal glycemic control when their HbA1c was < 7.5% . Microalbuminuria was assayed using SERA-PAK immuno-microalbumin Kit (Bayer Corporation, Benedict Ave, Tarry town, NY, USA). Persistent microalbuminuria was defined when two of three samples showed urinary albumin excretion rate of 30-300 μg/mg creatinine . Two ml of venous blood were collected on EDTA tube, centrifuged for 15 minutes and plasma samples were stored at -70°C till assay. Plasma adrenomedullin level was assessed by ELISA technique using adrenomedullin (human) (EIA-3418) kit, DRG international Inc., USA).
Analysis of data was performed by using SPSS (version 15). Comparison between 2 groups of patients was made using Student's t-test for parametric measures and Wilcoxon signed-rank test (Z value) for non parametric measures. Spearman's rank correlation coefficient was used to correlate between two quantitative variables. P value < 0.05 was considered the cut-off value for significance.
Comparison between diabetic patients with and without MVC and controls as regards age, disease duration and laboratory findings.
Group 1 Patients with MVC (N = 15)
Group 2 Patients without MVC(N = 40)
Controls (N = 30)
Mean ± SD
Mean ± SD
Mean ± SD
17.13 ± 1.5
12.73 ± 2.7
12.83 ± 2.4
P1 < 0.001, P2 < 0.001, P3 > 0.05*
21.39 ± 3.25
23.27 ± 3.8
22.11 ± 3.23
P > 0.05*
Systolic BP percentile
70.48 ± 21.7
66.4 ± 26.4
67.5 ± 23.23
P > 0.05*
Diastolic BP percentile
68.84 ± 13.6
64.7 ± 19.8
66 ± 18.3
P > 0.05*
Duration of diabetes (yrs)
9.6 ± 3.3
3.8 ± 3.8
P < 0.001*
9.36 ± 1.8
8.09 ± 2.02
4.2 ± 0.4
P < 0.05*
110.6 ± 94.24
60.25 ± 31.76
39.2 ± 12.43
Z1-2.01, Z2-2.7, Z3-3.37
P1 = 0.04, P2 < 0.01, P3 = 0.001#
Median plasma adrenomedullin levels in patients with and without diabetic microangiopathy and control group
Nephropathy + retinopathy
Nephropathy + neuropathy
50.22 - 70.28
34.64 - 43.76
In the present study, diabetic patients showed highly significant increase in plasma AM levels compared to controls. These results are in agreement with Hayashi et al  who reported significant increase in plasma AM in hyperglycemic patients compared with normal volunteers. However, Kinoshita et al.  found that when patients with nephropathy were excluded, plasma levels of AM were not significantly different in old diabetic patients and healthy individuals.
Our patients with MVC displayed higher AM levels compared to those without. Similar results were reported in other studies [19, 20, 27]. Yet, they reported no significant difference in patients with nephropathy, neuropathy or retinopathy (P > 0.05). In the current study, highest AM levels were observed in diabetic patients with retinopathy and nephropathy. Higher plasma AM levels in our diabetic patients with microalbuminuria compared to normoalbuminuric patients differs from Garcia-Unzueta et al  who reported higher levels of AM and cAMP in patients with renal insufficiency but normal in microalbuminuric patients. Furthermore, adult type 1 diabetic patients with renal insufficiency had higher levels of plasma AM than diabetics with other complications, and plasma AM increase was proportionate to kidney function deterioration . Adrenomedullin could exert a wide range of vascular actions (mostly protective). These include endothelium-dependent and -independent vasodilatation, antioxidative stress, stimulation of endothelial nitric oxide production, antiproliferation of vascular smooth muscle cell, and adventitial fibroblast. Taken together, the elevation of plasma adrenomedullin level in type 1 diabetes(especially in the presence of nephropathy) could participate in the mechanism against progression of vascular damage .
Highest individual plasma AM values recorded in our diabetics with retinopathy are similar to previous studies [19, 29]. Adrenomedullin may also play a role in the neovascularization process that occurs after retinal ischemia. Increased AM levels in vitreous humor of patients with proliferative vitreoretinopathy [30, 31] and diabetic retinopathy  suggested the involvement of AM as a possible associated factor in the course of vascular and proliferative retinal diseases.
Increased AM levels with longer duration of diabetes is consistent with Garcia-Unzueta et al.  who reported similar relationship suggesting that the elevation of AM levels is a late phenomenon due to endothelial dysfunction. Also, there was a significant correlation between AM levels and HbA1c with higher HbA1c levels among diabetics with MVC. Similarly, Caliumi et al.  reported that increased circulating AM correlates with poor glucose metabolic control in type 2 diabetics. The elevated plasma AM level originates from vascular AM expression induced by hyperglycemia through protein kinase C-dependent pathway .
Our patients with MVC displaying higher AM levels were older than those without. However, no significant correlation was observed between AM and age. Similarly, Hayashi et al  reported no change in AM levels with age. Older age, longer duration of diabetes and puberty are known risk factors for MVC . It is still uncertain whether increased release of AM in diabetes is a compensatory mechanism or a coincident event. The precise role of AM in the pathogenesis of diabetic complications is still to be elucidated .
The increase in plasma adrenomedullin level in type 1 diabetic children and adolescents being correlated with disease duration and metabolic control; the two most independent risk factors for the occurrence of MVC; may declare its role in the pathogenesis of diabetic microangiopathy since childhood.
enzyme linked immune sorbent assay
Cyclic adenosine monophosphate
angiotensin converting enzyme.
We are grateful to the staff of the Diabetes Clinic, Children's Hospital, Ain Shams University.
- Sugo S, Minamino N, Kangawa K, Miyamoto K, Kitamura K, Sakata J, Eto T, Matsuo H: Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun. 1994, 201 (3): 1160-6. 10.1006/bbrc.1994.1827.View ArticlePubMedGoogle Scholar
- Sugo S, Minamino N, Shoji H, Kangawa K, Kitamura K, Eto T, Matsuo H: Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor-alpha. Biochem Biophys Res Commun. 1994, 203 (1): 719-26. 10.1006/bbrc.1994.2241.View ArticlePubMedGoogle Scholar
- Minamino N, Kikumoto K, Isumi Y: Regulation of adrenomedullin expression and release. Microsc Res Tech. 2002, 57 (1): 28-39. 10.1002/jemt.10048.View ArticlePubMedGoogle Scholar
- Bełtowski J, Jamroz A: Adrenomedullin--what do we know 10 years since its discovery?. Pol J Pharmacol. 2004, 56 (1): 5-27.PubMedGoogle Scholar
- Tomoda Y, Isumi Y, Katafuchi T, Minamino N: Regulation of adrenomedullin secretion from cultured cells. Peptides. 2001, 22 (11): 1783-94. 10.1016/S0196-9781(01)00519-8.View ArticlePubMedGoogle Scholar
- Miyashita K, Itoh H, Sawada N, Fukunaga Y, Sone M, Yamahara K, Yurugi T, Nakao K: Adrenomedullin promotes proliferation and migration of cultured endothelial cells. Hypertens Res. 2003, 26 (Suppl): S93-8. 10.1291/hypres.26.S93.View ArticlePubMedGoogle Scholar
- Bunton DC, Petrie MC, Hillier C, Johnston F, McMurray JJ: The clinical relevance of adrenomedullin: a promising profile?. Pharmacol Ther. 2004, 103 (3): 179-201. 10.1016/j.pharmthera.2004.07.002.View ArticlePubMedGoogle Scholar
- Julián M, Cacho M, Garcia MA, Martin-Santamaria S, de Pascual-Teresa B, Ramos A, Martinez A, Cuttitta F: Adrenomedullin: a new target for the design of small molecule modulators with promising pharmacological activities. Eur J Med Chem. 2005, 40 (8): 737-50. 10.1016/j.ejmech.2004.10.016.View ArticlePubMedGoogle Scholar
- Garcia-Unzueta MT, Berrazueta JR, Pesquera C, Obaya S, Fernández MD, Sedano C, Amado JA: Levels of plasma total adrenomedullin are related with two acute phase inflammatory reactants (fibrinogen and sialic acid) but not with markers of endothelial dysfunction in type 1 diabetes adrenomedullin and vascular risk factors in type 1 DM. J Diabetes Complications. 2005, 19 (3): 147-54. 10.1016/j.jdiacomp.2004.08.002.View ArticlePubMedGoogle Scholar
- Rizicska E, Toth M, Tulassay Z, Somogyi A: Adrenomedullin and diabetes mellitus. Diabetes Metab Res Rev. 2001, 17 (5): 321-9. 10.1002/dmrr.223.View ArticleGoogle Scholar
- Shimosawa T, Shibagaki Y, Ishibashi K, Kitamura K, Kangawa K, Kato S, Ando K, Fujita T: Adrenomedullin, an endogenous peptide, counteracts cardiovascular damage. Circulation. 2002, 105 (1): 106-111. 10.1161/hc0102.101399.View ArticlePubMedGoogle Scholar
- Katsuki A, Sumida Y, Urakawa H, Gabazza EC, Maruyama N, Morioka K, Kitagawa N, Hori Y, Nakatani K, Yano Y, Adachi Y: Increased oxidative stress is associated with elevated plasma levels of adrenomedullin in hypertensive patients with type 2 diabetes. Diabetes Care. 2003, 26 (5): 1642-3. 10.2337/diacare.26.5.1642.View ArticlePubMedGoogle Scholar
- Nikitenko LL, Smith DM, Hague S, Wilson CR, Bicknell R, Rees MCP: Adrenomedullin and the microvasculature. Trends Pharmacol Sci. 2002, 23 (3): 101-3. 10.1016/S0165-6147(00)01983-0.View ArticlePubMedGoogle Scholar
- Ribatti D, Nico B, Spinazzi R, Vacca A, Nussdorfer GG: The role of adrenomedullin in angiogenesis. Peptides. 2005, 26 (9): 1670-5. 10.1016/j.peptides.2005.02.017.View ArticlePubMedGoogle Scholar
- Ribatti D, Conconi MT, Nussdorfer GG: Non classic endogenous novel [corrected] regulators of angiogenesis. Pharmacol Rev. 2007, 59 (2): 185-205. 10.1124/pr.59.2.3.View ArticlePubMedGoogle Scholar
- Di Iorio R, Marinoni E, Urban G, Costantini A, Cosmi EV, Letizia C: Fetomaternal adrenomedullin levels in diabetic pregnancy. Horm Metab Res. 2001, 33 (8): 486-90. 10.1055/s-2001-16942.View ArticlePubMedGoogle Scholar
- Martínez A, Weaver C, López J, Bhathena SJ, Elsasser TH, Miller MJ, Moody TW, Unsworth EJ, Cuttitta F: Regulation of insulin secretion and blood glucose metabolism by adrenomedullin. Endocrinology. 1996, 137 (6): 2626-32. 10.1210/en.137.6.2626.PubMedGoogle Scholar
- Zudaire E, Cuttitta F, Martínez A: Regulation of pancreatic physiology by adrenomedullin and its binding protein. Regul Pept. 2003, 112 (1-3): 121-30. 10.1016/S0167-0115(03)00030-2.View ArticlePubMedGoogle Scholar
- Garcia-Unzueta MT, Montalban C, Pesquera C, Berrazueta JR, Amado JA: Plasma adrenomedullin levels in type 1 diabetes: Relationship with clinical parameters. Diabetes Care. 1998, 21 (6): 999-1003. 10.2337/diacare.21.6.999.View ArticlePubMedGoogle Scholar
- Lim SC, Morgenthaler NG, Subramaniam T, Wu YS, Goh SK, Sum CF: The relationship between adrenomedullin, metabolic factors, and vascular function in individuals with type 2 diabetes. Diabetes Care. 2007, 30 (6): 1513-9. 10.2337/dc06-1899.View ArticlePubMedGoogle Scholar
- Dorchy H: Screening for subclinical complications in young type 1 diabetic patients: Experience acquired in Brussels. Pediatr Endocrinol Rev. 2004, 1 (4): 380-403.PubMedGoogle Scholar
- Goldstein DE, Little RR, Wiedmeyer HM, England JD, McKenzie EM: Glycated hemoglobin: methodologies and clinical applications. Clin Chem. 1986, 32 (10 Suppl): B64-70.PubMedGoogle Scholar
- Rewers M, Pihoker C, Donaghue K, Hanas R, Swift P, Klingensmith GJ, International Society for Pediatric and Adolescent Diabetes (ISPAD): Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes. 2007, 8 (6): 408-10.1111/j.1399-5448.2007.00352.x.View ArticlePubMedGoogle Scholar
- Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, Steffes MW, Striker GE, Viberti GC: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995, 346 (8982): 1080-1084. 10.1016/S0140-6736(95)91747-0.View ArticlePubMedGoogle Scholar
- Hayashi M, Shimosawa T, Isaka M, Yamada S, Fujita R, Fujita T: Plasma adrenomedullin in diabetes. Lancet. 1997, 350 (9089): 1449-1450. 10.1016/S0140-6736(05)64211-0.View ArticlePubMedGoogle Scholar
- Kinoshita H, Kato K, Kuroki M, Nakamura S, Kitamura K, Hisanaga S, Fujimoto S, Eto T: Plasma adrenomedullin levels in patients with diabetes. Diabetes Care. 2000, 23 (2): 253-254. 10.2337/diacare.23.2.253.View ArticlePubMedGoogle Scholar
- Nakamura T, Honda K, Ishikawa S, Kitamura K, Eto T, Saito T: Plasma adrenomedullin levels in patients with non-insulin dependent diabetes mellitus: Close relationships with diabetic complications. Endocr J. 1998, 45 (2): 241-6. 10.1507/endocrj.45.241.View ArticlePubMedGoogle Scholar
- Kato J, Tsuruda T, Kita T, Kitamura K, Eto T: Adrenomedullin: a protective factor for blood vessels. Arterioscler Thromb Vasc Biol. 2005, 25 (12): 2480-7. 10.1161/01.ATV.0000184759.91369.f8.View ArticlePubMedGoogle Scholar
- Zakareia FA, Alderees AA, Al Regaiy KA, Alrouq FA: Correlation of electroretinography b-wave absolute latency, plasma levels of human basic fibroblast growth factor, vascular endothelial growth factor, soluble fatty acid synthase, and adrenomedullin in diabetic retinopathy. J Diabetes Complications. 2009,Google Scholar
- Udono T, Takahashi K, Takano S, Shibahara S, Tamai M: Elevated adrenomedullin in the vitreous of patients with proliferative vitreo-retinopathy. Am J Opthahlmol. 1999, 128 (6): 765-767. 10.1016/S0002-9394(99)00247-0.View ArticleGoogle Scholar
- Udono T, Takahashi K, Abe T, Shibahara S, Tamai M: Elevated immunoreactive-adrenomedullin levels in the aqueous humor of patients with uveitis and vitreoretinal disorders. Peptides. 2002, 23 (10): 1865-8. 10.1016/S0196-9781(02)00145-6.View ArticlePubMedGoogle Scholar
- Er H, Doganay S, Ozerol E, Yürekli M: Adrenomedullin and leptin levels in diabetic retinopathy and retinal diseases. Opthalmologica. 2005, 219 (2): 107-11. 10.1159/000083270.View ArticleGoogle Scholar
- Caliumi C, Balducci S, Petramala L, Cotesta D, Zinnamosca L, Cianci R, Di Donato D, Vingolo EM, Fallucca F, Letizia C: Plasma levels of adrenomedullin, a vasoactive peptide, in type 2 diabetic patients with and without retinopathy. Minerva Endocrinol. 2007, 32 (2): 73-8.PubMedGoogle Scholar
- Hayashi M, Shimosawa T, Fujita T: Hyperglycemia increases vascular adrenomedullin expression. Biochem Biophys Res Commun. 1999, 258 (2): 453-456. 10.1006/bbrc.1999.0664.View ArticlePubMedGoogle Scholar
- Donaghue KC, Craig ME, Chan AK, Fairchild JM, Cusumano JM, Verge CF, Crock PA, Hing SJ, Howard NJ, Silink M: Prevalence of diabetes complications 6 years after diagnosis in an incident cohort of childhood diabetes. Diabet Med. 2005, 22 (6): 711-8. 10.1111/j.1464-5491.2005.01527.x.View ArticlePubMedGoogle Scholar
- Ruzicska E, Tóth M, Tulassay Z, Somogyi A: [Adrenomedullin under physiologic and pathologic conditions]. Orv Hetil. 2001, 142 (19): 987-92.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.